Speciality medical devices provider Teleflex Incorporated has purchased Semprus BioSciences' Sustain technology for an upfront payment of $30m.
The covalently bonded, non-leaching polymer Sustain technology mimics the chemical properties of endothelial cell membrane and reduces the attachment of platelets and blood proteins at the device surface.
In vitro testing and in vivo animal testing of Sustain technology, with exposure to blood over several months, have shown to reduce thrombus accumulation.
Teleflex chairman, president and CEO, Benson Smith, said the acquisition illustrates the company's commitment to invest in late-stage technologies to support future growth.
"We believe Semprus' novel technology provides distinct advantages over other surface and coating technologies currently on the market, with its dual-functionality, ability to work in blood products and long-term duration," Smith added.
"Furthermore, we are excited about the potential for a broad array of our products with this technology to reduce infection- and thrombus-related complications for patients, as well as the resulting substantial healthcare costs which often arise when medical devices are implanted in the body.
"Finally, with the recently 510(k)-cleared antithrombogenic claims on our existing ARROW PICC with Chlorag+ard technology, which is a chlorhexidine-based coating, we feel Semprus' Sustain technology provides us with a tremendous next-generation platform for continued innovation."
Based on the achievement of regulatory and revenue milestones over the next several years, certain additional payments will be made by Teleflex.
Semprus BioSciences co-founder and Semprus technology VP, David Lucchino, said: "We look forward to being a catalyst for continued growth through the development and rollout of the Sustain technology on medical devices around the world."